Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453205 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT01453205 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 187 participants.
The verdict
NCT01453205, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.
Interventions
- DRUG Rituximab
- PROCEDURE Autologous Stem Cell Transplant (ASCT)
- DRUG ICE
- DRUG DHAP
- DRUG MEDI-551 2 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2012-02-27 |
| Est. Completion | 2016-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453205
The ClinicalTrials.gov registry entry for NCT01453205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT01453205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453205 about?
NCT01453205 is a clinical study titled "A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has s...
What is the current status of trial NCT01453205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2012-02-27. Estimated completion is 2016-07-11.
What interventions are being tested in trial NCT01453205?
The interventions under investigation include: Rituximab (DRUG), Autologous Stem Cell Transplant (ASCT) (PROCEDURE), ICE (DRUG), DHAP (DRUG), MEDI-551 2 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01453205?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.